These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 26879277

  • 1. Ozanimod: a better or just another S1P receptor modulator?
    Sørensen PS.
    Lancet Neurol; 2016 Apr; 15(4):345-7. PubMed ID: 26879277
    [No Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW, RADIANCE Study Group.
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [Abstract] [Full Text] [Related]

  • 3. Ozanimod: First Approval.
    Lamb YN.
    Drugs; 2020 Jun; 80(8):841-848. PubMed ID: 32385738
    [Abstract] [Full Text] [Related]

  • 4. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
    Rasche L, Paul F.
    Expert Opin Pharmacother; 2018 Dec; 19(18):2073-2086. PubMed ID: 30407868
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L, RADIANCE Trial Investigators.
    Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
    [Abstract] [Full Text] [Related]

  • 6. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.
    Taylor Meadows KR, Steinberg MW, Clemons B, Stokes ME, Opiteck GJ, Peach R, Scott FL.
    PLoS One; 2018 Aug; 13(4):e0193236. PubMed ID: 29608575
    [Abstract] [Full Text] [Related]

  • 7. Ozanimod for the treatment of relapsing forms of multiple sclerosis.
    Kuczynski AM, Oh J.
    Neurodegener Dis Manag; 2021 Jun; 11(3):207-220. PubMed ID: 34011158
    [Abstract] [Full Text] [Related]

  • 8. An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis.
    Fronza M, Lorefice L, Frau J, Cocco E.
    Drug Des Devel Ther; 2021 Jun; 15():1993-2004. PubMed ID: 34007159
    [Abstract] [Full Text] [Related]

  • 9. Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS.
    Harris S, Tran JQ, Southworth H, Spencer CM, Cree BAC, Zamvil SS.
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32737072
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.
    Kappos L, Arnold DL, Bar-Or A, Camm J, Derfuss T, Kieseier BC, Sprenger T, Greenough K, Ni P, Harada T.
    Lancet Neurol; 2016 Oct; 15(11):1148-59. PubMed ID: 27543447
    [Abstract] [Full Text] [Related]

  • 11. Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis.
    Nie T, Syed YY.
    CNS Drugs; 2024 Nov; 38(11):931-941. PubMed ID: 39368032
    [Abstract] [Full Text] [Related]

  • 12. Ozanimod (Zeposia) for multiple sclerosis.
    Med Lett Drugs Ther; 2020 Aug 24; 62(1605):132-134. PubMed ID: 32970043
    [No Abstract] [Full Text] [Related]

  • 13. Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
    Selmaj KW, Cohen JA, Comi G, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Havrdova EK, Cree BAC, Minton N, Sheffield JK, Ding N, Kappos L.
    Mult Scler Relat Disord; 2021 Jun 24; 51():102844. PubMed ID: 33892317
    [Abstract] [Full Text] [Related]

  • 14. Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.
    Tran JQ, Hartung JP, Peach RJ, Boehm MF, Rosen H, Smith H, Brooks JL, Timony GA, Olson AD, Gujrathi S, Frohna PA.
    J Clin Pharmacol; 2017 Aug 24; 57(8):988-996. PubMed ID: 28398597
    [Abstract] [Full Text] [Related]

  • 15. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis.
    Rowan C, Ungaro R, Mehandru S, Colombel JF.
    Expert Opin Pharmacother; 2022 Jun 24; 23(8):893-904. PubMed ID: 35503955
    [Abstract] [Full Text] [Related]

  • 16. A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis.
    Aoun R, Hanauer S.
    Expert Rev Gastroenterol Hepatol; 2022 May 24; 16(5):411-423. PubMed ID: 35400292
    [Abstract] [Full Text] [Related]

  • 17. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA.
    Mult Scler; 2022 Oct 24; 28(12):1944-1962. PubMed ID: 35765217
    [Abstract] [Full Text] [Related]

  • 18. Discovery of a brain-penetrant S1P₃-sparing direct agonist of the S1P₁ and S1P₅ receptors efficacious at low oral dose.
    Demont EH, Arpino S, Bit RA, Campbell CA, Deeks N, Desai S, Dowell SJ, Gaskin P, Gray JR, Harrison LA, Haynes A, Heightman TD, Holmes DS, Humphreys PG, Kumar U, Morse MA, Osborne GJ, Panchal T, Philpott KL, Taylor S, Watson R, Willis R, Witherington J.
    J Med Chem; 2011 Oct 13; 54(19):6724-33. PubMed ID: 21838322
    [Abstract] [Full Text] [Related]

  • 19. In vitro assessment of the binding and functional responses of ozanimod and its plasma metabolites across human sphingosine 1-phosphate receptors.
    Selkirk JV, Yan YG, Ching N, Paget K, Hargreaves R.
    Eur J Pharmacol; 2023 Feb 15; 941():175442. PubMed ID: 36470447
    [Abstract] [Full Text] [Related]

  • 20. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice.
    Poti F, Costa S, Bergonzini V, Galletti M, Pignatti E, Weber C, Simoni M, Nofer JR.
    Vascul Pharmacol; 2012 Aug 19; 57(1):56-64. PubMed ID: 22459073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.